+ CD20 − ) could represent the lymphoid differentiation of the neoplastic clone, which could be predominant in the lymphoid blast crisis in CML. These findings should be confirmed using sorting methods or by combining immunophenotyping with FISH.
× 14 mg/m 2 Idarubicin during induction: results of a pilot study in children with AML
TO THE EDITOR Idarubicin (IDR) is one of the most effective, but also toxic drugs in the treatment of AML. A finding, which was supported by several trials in adults, comparing induction regimens with daunorubicin (DNR) vs IDR which resulted in higher complete remission (CR) rates in the IDR group. 1 The standard dose applied in children and adults is 8-12 mg/m 2 during induction. To further improve results we increased the IDR dose from 12 mg/m 2 as given in study AML-BFM 93 during induction (AIE = Ara-C, idarubicin, etoposide) to 14 mg/m 2 in a pilot study. Seventeen children and adolescents (16 with de novo AML, one with secondary AML) from 11 hospitals (Dü sseldorf, Freiburg, Hamburg, Hannover, Homburg/Saar, Münster, Ulm, Tü bingen, Mü nchen, Wien, Jena) were included (pilot group A). Informed consent from the children or parents was obtained. Outcome and toxicities were compared with the other 447 patients of study AML-BFM 93, enrolled until April 1998, who were treated with 12 mg/m 2 /day × 3 days IDR (group B) or 2 × 30 mg/m 2 /day × 3 days DNR (group C) during induction. Further treatment consisted of a 6-week consolidation therapy with seven different drugs in standard risk patients (M1/M2 with Auer rods and M4eo and a blast cell reduction on day 15р5%, M3 all patients), 2 whereas high risk patients (all others) received an additional block high-dose Ara-C plus mitoxantrone (HAM). Then, all patients were treated with one block of high-dose Ara-C plus VP-16, cranial irradiation with 18 Gy (standard dose in children у3 years) and maintenance therapy for a total duration of 18 months. 3 Our analysis focused on the evaluation of therapy-induced toxicities, including those occurring after the second and third therapy block in order to gain more knowledge about the influence of induc- CR was defined according to the CALGB criteria. Patients not having achieved CR until the end of intensification treatment were allocated to nonresponders. Follow-up was as of February 1999.
Patient characteristics of group A are shown in Table 1 . Differences in FAB distribution, gender, leukocyte count and bone marrow blasts on day 15 between group A and groups B and C (data not shown) were not significant. However, slightly more patients of group A had unfavorable criteria, eg FAB type MO (3/17 patients = 18% vs 22/447 = 5%, P (Fisher test) = 0.09), or unfavorable immunology (biphenotypical features with expression of cyCD3, 2 patients), unfavorable cytogenetics (t(11;19) or complex aberrations, 4 patients) and hyperleukocytosis (2 patients, one extreme).
Overall results of group A are presented in Table 2 in comparison with groups B and C. Blast cell reduction on day 15 in the BM was significantly better in children treated with IDR (12 and 14 mg/m 2 ) compared to patients treated with DNR (P ( 2 ) = 0.035). Sixteen of 17 group A patients (94%) achieved remission, which was not significantly different to the other groups. Relapse rate was low in group A and B, (cumulative incidence 20%, s.e. 12% and 24%, s.e. 4%) but also low in group C (21%, s.e. 4%). However, follow-up is still short.
Overall, induction treatment in group A patients was feasible, but quite toxic, due to severe aplasia (in median 25 days, range 12-66 days) after starting induction to neutrophil recovery Ͼ500/l. However, not significantly longer compared to group B1 and C1 with 25.0 (12-47) and 23.0 (13-60) days, respectively (Table 3) . Duration of thrombopenia Ͻ20 000/l in group A patients was 21.0 (10-66) days compared to 19.0 (13-56) days in group C1 patients, P (U-test) = 0.08.
Four patients suffered from severe (grade 3/4) sepsis and pneumonia. Another six patients showed fever of unknown origin (FUO) for 4-12 days. Severe mucositis (grade 3/4) occurred in four patients. Cardiotoxicity (defined by decreased shortening fraction) was not seen. Compared to group B1 and C1 the number of patients with infections was not significantly higher in group A (Table 3) . Mucositis (уWHO grade 2) has often been seen in group A and B1 and rarely in group C1. The difference was also not significant (P = 0.31). The second treatment block was followed by severe toxicities in four patients of group A. On day 15 after AIE induction, two of them presented with 48% and 32% BM blasts, respectively, and received further treatment in aplasia. Both suffered from severe infections. Patient No. 5 died in aplasia from invasive pulmonary aspergillosis. Patient No. 6 showed increasing liver and spleen enlargement. However, late complete remission after 6 weeks low-dose Ara-C treatment was achieved.
The third patient (No. 10) was already admitted to the hospital with mycoplasma pneumonia. After HAM treatment he experienced severe Staphylococcus aureus sepsis together with encephalopathy (central neurotoxicity grade 3) and mucositis grade 2. After hematopoietic recovery and achieving remission he remained in good condition. Patient No. 17 suffered from severe fungal sepsis (aspergillosis) after HAM treatment.
During the 3rd treatment course, two of 11 children treated showed severe toxicities. Patient No. 1 suffered from the same infection which had already occurred during induction (sepsis grade 3 caused by Streptococcus mitis) with diarrhea. Patient No. 9 was a 12-year-old girl with Streptococcus sepsis during induction. She achieved remission after induction and was febrile for 10 days with intestinal hemorrhage after HAM treatment. The consolidation course was stopped after 3 weeks due to FUO in severe aplasia. She died from aspergillosis after 51 days of aplasia. There was no recovery of the neutrophils with G-CSF treatment.
By comparing duration of aplasia and rate of severe infections during and after the 2nd and 3rd treatment block (data not shown), significant differences could not be seen between patients of group A and the other groups. Other toxicities, eg mucositis, hemorrhage, liver-and cardiotoxicity were rare and occurred as frequently as in the other groups.
Results of this pilot study in children and adolescents with an increased dose of IDR during induction were promising concerning remission rate. The response rate was very good, despite a high percentage of patients presenting with unfavorable risk factors, eg hyperleukocytosis, biphenotypic features or M0 phenotype. However, the toxicity rate due to long-term aplasia with severe infections was high in four of 17 patients. With our standard ADE treatment grade 3 and 4 mucositis have rarely been seen. Daghestani et al 4 reported mucositis to be the most common side-effect in one-third of adult patients treated with 20 to 45 mg/m 2 idarubicin over 2 to 3 days. Wiernik et al 5 found similar toxicities, as seen in our patients, in adults treated with IDR with a longer recovery of WBC and platelets compared to DNR patients. In two other adult trials comparing idarubicin and DNR 1 the overall incidence of infection during consolidation therapy was higher in the idarubicin arm, suggesting a higher cumulative marrow toxicity with IDR. Early cardiotoxicity was not seen in pilot group A treated with a higher anthracycline dose, however, follow-up is still short.
We conclude that the IDR 14 mg/m 2 regimen was an effective, but also toxic therapy, however, not significantly different compared to the IDR 12 mg/m 2 treatment. We stopped the pilot study, because the dose intensification did not show any benefit for the patients of this group. However, our experiences are based on a small patient number.
